<DOC>
	<DOCNO>NCT02105584</DOCNO>
	<brief_summary>This prospective , non-randomized , study safety efficacy Occlutech® LAA occluder indicate percutaneous LAA closure adult male female patient atrial fibrillation . Safety efficacy assess day 1 , 30 90 , 1 year follow implantation Occlutech® LAA Occluder .</brief_summary>
	<brief_title>Prospective , Non-randomized , Safety Efficacy Study New Occluder Design Minimally Invasive Closure Left Atrial Appendage ( LAA ) Patients With Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Documented paroxysmal , persistent chronic nonvalvular AF Calculated CHA2DS2 VASC score equal great 2 and/or HASBLED score equal great 2 Patients eligible noneligible lifelong , oral anticoagulation therapy Life expectancy least 1 year Written , inform consent patient her/his legallyauthorized representative participation study Suspected known intracardiac thrombus NYHA Class IV CHF Patients unstable intractable angina pectoris ASD and/or atrial septal repair closure device Recent myocardial infarction within 3 month Severe valvular heart disease , implanted mechanical valve prosthesis Large PFO significant atrial septal aneurysm Planned ablation procedure within 30 day Occlutech LAA occluder® implant Resting heart rate &gt; 110 bpm Allergy Nitinol , result nickel and/or titanium allergy Stroke/TIA within last 30 day Thrombocytopenia , thrombocytosis , leukopenia , anemia Symptomatic carotid artery disease LVEF &lt; 30 % Mitral valve stenosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>